Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Myristyl nicotinate

🥰Excellent
Catalog No. T19438Cas No. 273203-62-6
Alias Tetradecyl nicotinate

Myristyl nicotinate (Tetradecyl nicotinate) is an ester prodrug being developed for delivering nicotinic acid (NIC) into the skin to prevent actinic keratosis and its progression to skin cancer.

Myristyl nicotinate

Myristyl nicotinate

🥰Excellent
Purity: 99.50%
Catalog No. T19438Alias Tetradecyl nicotinateCas No. 273203-62-6
Myristyl nicotinate (Tetradecyl nicotinate) is an ester prodrug being developed for delivering nicotinic acid (NIC) into the skin to prevent actinic keratosis and its progression to skin cancer.
Pack SizePriceAvailabilityQuantity
1 mL x 10 mM (in DMSO)$29In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Myristyl nicotinate"

Select Batch
Purity:99.50%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Myristyl nicotinate (Tetradecyl nicotinate) is an ester prodrug being developed for delivering nicotinic acid (NIC) into the skin to prevent actinic keratosis and its progression to skin cancer.
In vitro
Myristyl nicotinate is an ester prodrug under development for delivery of nicotinic acid to skin for treatment and prevention of conditions that involve skin barrier impairment such as chronic photodamage and atopic dermatitis or for mitigating skin barrier impairment that results from therapy such as retinoids or steroids[1].?The formulation stability of Myristyl nicotinate is crucial because even small amounts of free nicotinic acid cause skin flushing, an effect that is not harmful but would severely limit tolerability[1].
In vivo
Retinoic acid therapy resulted in stratum corneum thinning of approximately 25% (P = 0.006 versus baseline) that was ameliorated by Myristyl nicotinate use (P < 0.005). Therapy resulted in an increased rate of transepidermal water loss (TEWL) of approximately 45% (P = 0.001 versus baseline) and use of Myristyl nicotinate protected against the increase in TEWL with the strongest protection provided by prior use of Myristyl nicotinate (P = 0.056 versus placebo). Myristyl nicotinate use reduced the incidence of side-effects of the therapy and again prior use provided the greatest reduction of side-effects. Subjects showed statistically significant clinical improvement (P < 0.05 versus baseline) during the study. Myristyl nicotinate use did not interfere with any clinical improvement parameters and improved effects on temple laxity (P = 0.01 versus placebo). Analysis of changes in epidermal thickness, Ki67-positive cells and intensity of loricrin staining demonstrated that Myristyl nicotinate either improved or did not interfere with retinoic acid efficacy. These results show that prior and concurrent use of Myristyl nicotinate can mitigate barrier impairment and improve the tolerability of retinoic acid therapy for facial photodamage without interfering with efficacy[1].
AliasTetradecyl nicotinate
Chemical Properties
Molecular Weight319.48
FormulaC20H33NO2
Cas No.273203-62-6
SmilesCCCCCCCCCCCCCCOC(=O)c1cccnc1
Relative Density.0.953 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 15 mg/mL (46.95 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.1301 mL15.6504 mL31.3009 mL156.5043 mL
5 mM0.6260 mL3.1301 mL6.2602 mL31.3009 mL
10 mM0.3130 mL1.5650 mL3.1301 mL15.6504 mL
20 mM0.1565 mL0.7825 mL1.5650 mL7.8252 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Myristyl nicotinate | purchase Myristyl nicotinate | Myristyl nicotinate cost | order Myristyl nicotinate | Myristyl nicotinate chemical structure | Myristyl nicotinate in vivo | Myristyl nicotinate in vitro | Myristyl nicotinate formula | Myristyl nicotinate molecular weight